Recognition of an impairment loss on intangible assets and a special loss in standalone financial statements (Japanese GAAP)
Astellas Pharma Inc.
Intangible assets related to resamirigene bilparvovec (AT132), the next-generation gene therapy ASP2957, and shares in Ogeda B.V., a subsidiary
The value of the assets was reassessed following the strategic discontinuation of the AT132 program and the reallocation of resources to ASP2957. The substantive value of the shares in Ogeda B.V., a subsidiary, declined below their carrying amount.
¥16.4 billion (consolidated financial statements, other expenses) / ¥74.8 billion (standalone financial statements, impairment loss on investments in subsidiaries and affiliates, recognized as a special loss; eliminated in consolidation and with no impact on consolidated profit or loss)
Q4 FY2025
Company response
Strategic discontinuation of the AT132 program
Reallocation of resources to ASP2957
| Item | Details |
|---|---|
| Event name | Recognition of an impairment loss on intangible assets and a special loss in standalone financial statements (Japanese GAAP) |
| Subject Entity | Astellas Pharma Inc. |
| Target Locations / Products | Intangible assets related to resamirigene bilparvovec (AT132), the next-generation gene therapy ASP2957, and shares in Ogeda B.V., a subsidiary |
| Cause | The value of the assets was reassessed following the strategic discontinuation of the AT132 program and the reallocation of resources to ASP2957. The substantive value of the shares in Ogeda B.V., a subsidiary, declined below their carrying amount. |
| Amount of Impact on Business Performance | ¥16.4 billion (consolidated financial statements, other expenses) / ¥74.8 billion (standalone financial statements, impairment loss on investments in subsidiaries and affiliates, recognized as a special loss; eliminated in consolidation and with no impact on consolidated profit or loss) |
| Accounting period in which recognized | Q4 FY2025 |
| Suspended operations | Strategic discontinuation of the AT132 program |
| Outlook | Reallocation of resources to ASP2957 |
Items this document does not state (17)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.The value of the assets was reassessed following the strategic discontinuation of the AT132 program and the reallocation of resources to the next-generation gene therapy ASP2957. The substantive value of the shares in Ogeda B.V., a subsidiary, declined below their carrying amount.